Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
FAS 355 DAUNORUBICIN CHEMBL178 NCI 10216102
FAS 355 TESTOSTERONE CHEMBL386630 NCI 10809356
FAS 355 VITAMIN K CHEMBL1201519 NCI 10930097
FAS 355 TRETINOIN CHEMBL38 NCI 9792441
FAS 355 CHOLECALCIFEROL CHEMBL1042 NCI 9811059
FAS 355 ARSENIC TRIOXIDE CHEMBL1200978 NCI 14719092
FAS 355 CYCLOPHOSPHAMIDE CHEMBL88 NCI 11437491
FAS 355 LITHIUM CHEMBL2146126 NCI 15475000
FAS 355 TENIPOSIDE CHEMBL452231 NCI 9543255
FAS 355 FLUOROURACIL CHEMBL185 NCI 12845662
FAS 355 MYCOPHENOLIC ACID CHEMBL866 NCI 14659903
FAS 355 VESNARINONE CHEMBL17423 NCI 9226479
FAS 355 RIZATRIPTAN CHEMBL905 GuideToPharmacologyInteractions, NCI 10974031, 12660450
FAS 355 SODIUM BUTYRATE CHEMBL62381 NCI 10444408, 10720760
FAS 355 ASPIRIN CHEMBL25 NCI 15200494
FAS 355 FLOXURIDINE CHEMBL917 NCI 11115403
FAS 355 ATORVASTATIN CHEMBL1487 NCI 16796407
FAS 355 THROMBIN CHEMBL2108110 NCI 16271051
FAS 355 VALPROIC ACID CHEMBL109 NCI 16328060
FAS 355 CHLORFENSON CHEMBL499017 NCI 9759874
FAS 355 EDELFOSINE CHEMBL28509 NCI 16540473

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
FAS rs2234767 AA + AG Platinum compounds efficacy no No significant difference in response rates were seen between the genotype groups. Response was defined as experiencing complete or partial remission; non-response was stable or progressive disease. Genotypes AA + AG is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. 22821704 1184137507